Arun Azad

13.2k total citations · 4 hit papers
261 papers, 6.1k citations indexed

About

Arun Azad is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Arun Azad has authored 261 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Pulmonary and Respiratory Medicine, 109 papers in Oncology and 98 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Arun Azad's work include Prostate Cancer Treatment and Research (187 papers), Radiopharmaceutical Chemistry and Applications (95 papers) and PARP inhibition in cancer therapy (53 papers). Arun Azad is often cited by papers focused on Prostate Cancer Treatment and Research (187 papers), Radiopharmaceutical Chemistry and Applications (95 papers) and PARP inhibition in cancer therapy (53 papers). Arun Azad collaborates with scholars based in Australia, United States and Canada. Arun Azad's co-authors include Kim N., Martin Gleave, Bernhard J. Eigl, Alexander W. Wyatt, Neal D. Shore, Christian Kollmannsberger, Michael S. Hofman, Andrew J. Armstrong, Arnulf Stenzl and Taro Iguchi and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Arun Azad

245 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

2019 686 citations Arun Azad et al. Journal of Clinical Oncology profile →
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

2015 367 citations Arun Azad, Stanislav Volik et al. Clinical Cancer Research profile →
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

2018 347 citations Matti Annala, Gillian Vandekerkhove et al. Cancer Discovery profile →
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

2022 169 citations Arun Azad et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Arun Azad

Since Specialization

Citations

This map shows the geographic impact of Arun Azad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arun Azad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arun Azad more than expected).

Fields of papers citing papers by Arun Azad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arun Azad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arun Azad. The network helps show where Arun Azad may publish in the future.

Co-authorship network of co-authors of Arun Azad

This figure shows the co-authorship network connecting the top 25 collaborators of Arun Azad. A scholar is included among the top collaborators of Arun Azad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arun Azad. Arun Azad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of 20 Cycles of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer 2025 ·Journal of Nuclear Medicine ·(unknown), James P Buteau, (unknown), Edmond M. Kwan, Shahneen Sandhu, Arun Azad, Michael S. Hofman	1
2	BRCA Mutation Testing in Men With Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice 2025 ·Asia-Pacific Journal of Clinical Oncology ·Arun Azad, Howard Gurney, (unknown), Jeffrey C. Goh, Vivek Rathi	0
3	MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY 2025 ·Urologic Oncology Seminars and Original Investigations ·Neeraj Agarwal, Michael T. Schweizer, Elena Castro, Arun Azad, Daniel J. George, Jayeta Chakrabarti, Sujata Narayanan, Yiyun Tang, Karim Fizazi	1
4	Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma 2025 ·British Journal of Urology ·Muhammad Shaiq Ali, Mathias Bressel, (unknown), (unknown), (unknown), (unknown), Declan G. Murphy, Renu Eapen, Marlon Perera, Nathan Lawrentschuk, Arun Azad, Sarat Chander, (unknown), Nicholas Hardcastle, Shankar Siva	0
5	Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer 2024 ·Radiation Oncology ·Muhammad Ali, Kendrick Koo, (unknown), (unknown), (unknown), Daniel Moon, Declan G. Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun Azad, Sarat Chander, Mark Shaw, Nicholas Hardcastle, Shankar Siva	2
6	Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Arun Azad, Craig Underhill, Howard Gurney, Lisa G. Horvath, Mark Voskoboynik, (unknown), (unknown), Ivan King, Frank Perabo, Guangyu Guo	1
7	CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Neeraj Agarwal, Arun Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Fred Saad, Axel S. Merseburger, Andrey Soares, Bradley A. McGregor, Bogdan Żurawski, Scott North, Marinos Tsiatas, Igor Bondarenko, (unknown), (unknown), Keerti Vardhan Sharma, (unknown), Roberta Ferraldeschi, Fong Wang, Sumanta K. Pal	20
8	Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Arun Azad, Karim Fizazi, Douglas Laird, Nobuaki Matsubara, Ugo De Giorgi, Consuelo Buttigliero, Lawrence I. Karsh, Jae Young Joung, Steven Yip, (unknown), Lee A. Albacker, Cynthia G. Healy, Xun Lin, Jijumon Chelliserry, Neeraj Agarwal	0
9	Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer 2023 ·Therapeutic Advances in Medical Oncology ·Louise Kostos, James P Buteau, Michael S. Hofman, Arun Azad	15
10	Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective? 2023 ·European Urology Oncology ·Niranjan Sathianathen, Nathan Lawrentschuk, Badrinath R. Konety, Arun Azad, Niall M. Corcoran, Damien Bolton, Declan G. Murphy	5
11	Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study 2021 ·European Journal of Cancer ·A. Antón, Shirley Wong, (unknown), Andrew Weickhardt, Arun Azad, Edmond M. Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey C. Goh, (unknown), Peter Gibbs, Ben Tran, (unknown)	8
12	ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901) 2021 ·British Journal of Urology ·Louise Emmett, Shalini Subramaniam, Anthony M. Joshua, Megan Crumbaker, Andrew Martin, Alison Y. Zhang, Nisha Rana, Ailsa Langford, Jenna Mitchell, Sonia Yip, Roslyn J. Francis, Michael S. Hofman, Shahneen Sandhu, Arun Azad, Craig Gedye, Margaret McJannett, Martin R. Stockler, Ian D. Davis, (unknown)	27
13	Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma 2020 ·European Urology Open Science ·J. Connor Wells, Shaan Dudani, Gan Chen, Igor Stukalin, Arun Azad, Elizabeth Liow, Frede Donskov, Takeshi Yuasa, Sumanta K. Pal, Gloria Velasco, Laura D. Wood, Aaron R. Hansen, Benoit Beuselinck, Christian Kollmannsberger, (unknown), Bradley A. McGregor, Mei Sheng Duh, Lynn Huynh, D.Y.C. Heng	1
14	Analytical Validation of an Error-Corrected Ultra-Sensitive Ctdna Next-Generation Sequencing Assay 2020 ·BioTechniques ·Heidi Fettke, Jason A. Steen, Edmond M. Kwan, Patricia Bukczynska, Shivakumar Keerthikumar, David L. Goode, Maria Docanto, Nicole Ng, Luciano G. Martelotto, Christine Hauser, Melissa C. Southey, Arun Azad, Tú Nguyen‐Dumont	5
15	Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer 2020 ·European Urology Focus ·Heidi Fettke, Edmond M. Kwan, Patricia Bukczynska, Nicole Ng, Tú Nguyen‐Dumont, Melissa C. Southey, Ian D. Davis, Andrew Mant, Phillip Parente, (unknown), Christine Hauser, Arun Azad	13
16	Prostate‐specific membrane antigen theranostics in advanced prostate cancer: an evolving option 2020 ·British Journal of Urology ·Nikhil Mayor, Niranjan Sathianathen, James P Buteau, (unknown), (unknown), Jada Kapoor, Arun Azad, Michael S. Hofman, Declan G. Murphy	17
17	Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer 2019 ·European Urology Focus ·Edmond M. Kwan, Heidi Fettke, Maria Docanto, Sarah Q. To, Patricia Bukczynska, Andrew Mant, David Pook, Nicole Ng, (unknown), Stefano Mangiola, Eva Segelov, Kate Mahon, Ian D. Davis, Phillip Parente, Carmel Pezaro, (unknown), Lisa G. Horvath, Arun Azad	11
18	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer breakdown → 2018 ·Cancer Discovery ·Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Evan W. Warner, Katherine Sunderland, Christian Kollmannsberger, Bernhard J. Eigl, Daygen L. Finch, Conrad D. Oja, Joanna Vergidis, Muhammad Zulfiqar, Arun Azad, Matti Nykter, Martin Gleave, Alexander W. Wyatt, Kim N.	347
19	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer breakdown → 2015 ·Clinical Cancer Research ·Arun Azad, Stanislav Volik, Alexander W. Wyatt, Anne Haegert, Stéphane Le Bihan, Robert H. Bell, Shawn Anderson, Brian McConeghy, Robert Shukin, Jenny Bazov, Jack Youngren, Pamela L. Paris, George Thomas, Eric J. Small, Yuzhuo Wang, Martin Gleave, Colin C. Collins, Kim N.	367
20	Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells 2011 ·Molecular Cancer Research ·Arun Azad, Susan Jackson, Carleen Cullinane, Anthony Natoli, Paul M. Neilsen, David F. Callen, Sauveur-Michel Maira, Wolfgang Hackl, Grant A. McArthur, Benjamin Solomon	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact